Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michelle Cochran

Psychiatry Nashville, TN Medical Doctor

NPI 1760587026 CMS profile 171388

2125 Belcourt Avenue, Neuroscience & Tms Treatment Center, Nashville, TN 37212

Open in the dashboard

General payments

$73,579

304 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Cochran of Nashville, TN is reported in the CMS Open Payments database as having received $73,579 across 304 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,579 26
2024 General $5,243 20
2023 General $28,367 75
2022 General $917 32
2021 General $1,299 53
2020 General $7,377 41
2019 General $18,796 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Cochran
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Michelle Cochran were reported at $11,579. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Michelle Cochran Psychiatry median Middle half National median
2019 $18,796 $184 $59–$605 $163
2020 $7,377 $119 $36–$372 $114
2021 $1,299 $143 $43–$576 $132
2022 $917 $153 $50–$590 $149
2023 $28,367 $170 $56–$651 $160
2024 $5,243 $179 $57–$673 $164
2025 $11,579 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $44,191 76 payments
  2. Neuronetics, Inc. $24,727 29 payments
  3. LivaNova USA, Inc. $638 5 payments
  4. Sunovion Pharmaceuticals Inc. $631 30 payments
  5. Alkermes, Inc. $579 23 payments
  6. AbbVie, Inc. $444 28 payments
  7. Axsome Therapeutics, Inc. $392 18 payments
  8. Allergan Inc. $280 17 payments
  9. Teva Pharmaceuticals USA, Inc. $241 7 payments
  10. Neurocrine Biosciences, Inc. $215 9 payments
  11. Other $1,242 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $39,320 11 payments
  2. Honoraria $18,000 4 payments
  3. Travel and Lodging $8,877 23 payments
  4. Food and Beverage $7,382 266 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $44,161 74 payments
  2. NEUROSTAR TMS THERAPY $24,727 29 payments
  3. LATUDA $631 30 payments
  4. LYBALVI Cns $541 21 payments
  5. LYBALVI Cns $459 17 payments
  6. LYBALVI Cns $441 16 payments
  7. LYBALVI Cns $441 16 payments
  8. VRAYLAR Neuroscience $412 26 payments
  9. Auvelity $392 18 payments
  10. VRAYLAR Neuroscience $311 19 payments
  11. Other $2,984 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

46

Median for Psychiatry & Neurology: 100

Drug cost

$639

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Olanzapine Generic 11 $260
Fluoxetine Hcl Generic 18 $221
Lamotrigine Generic 17 $158

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Pharmaceuticals, Inc $4,945
$4,945 — —
VRAYLAR
  • AbbVie, Inc. $100
$100 — —
Auvelity
  • Axsome Therapeutics, Inc. $55
$55 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $50
$50 — —
ARISTADA
  • Alkermes, Inc. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

304 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record